4.6 Article

Extracellular Vesicles Released by Genetically Modified Macrophages Activate Autophagy and Produce Potent Neuroprotection in Mouse Model of Lysosomal Storage Disorder, Batten Disease

Journal

CELLS
Volume 12, Issue 11, Pages -

Publisher

MDPI
DOI: 10.3390/cells12111497

Keywords

autophagy; Batten disease; drug delivery; extracellular vesicles; lysosomal storage disorders; neuroprotection

Categories

Ask authors/readers for more resources

We have developed a novel EV-based drug delivery system for the treatment of Batten disease (BD) by transporting the lysosomal enzyme TPP1. The EVs were loaded with TPP1 through transfection of parent cells and showed successful delivery to the brain in a mouse model of BD. The TPP1-loaded EVs exhibited therapeutic effects by eliminating lipofuscin aggregates, reducing inflammation, and improving neuronal survival, possibly through activation of the autophagy pathway. Continued research into effective therapies for BD is crucial for improving patient outcomes.
Over the recent decades, the use of extracellular vesicles (EVs) has attracted considerable attention. Herein, we report the development of a novel EV-based drug delivery system for the transport of the lysosomal enzyme tripeptidyl peptidase-1 (TPP1) to treat Batten disease (BD). Endogenous loading of macrophage-derived EVs was achieved through transfection of parent cells with TPP1-encoding pDNA. More than 20% ID/g was detected in the brain following a single intrathecal injection of EVs in a mouse model of BD, ceroid lipofuscinosis neuronal type 2 (CLN2) mice. Furthermore, the cumulative effect of EVs repetitive administrations in the brain was demonstrated. TPP1-loaded EVs (EV-TPP1) produced potent therapeutic effects, resulting in efficient elimination of lipofuscin aggregates in lysosomes, decreased inflammation, and improved neuronal survival in CLN2 mice. In terms of mechanism, EV-TPP1 treatments caused significant activation of the autophagy pathway, including altered expression of the autophagy-related proteins LC3 and P62, in the CLN2 mouse brain. We hypothesized that along with TPP1 delivery to the brain, EV-based formulations can enhance host cellular homeostasis, causing degradation of lipofuscin aggregates through the autophagy-lysosomal pathway. Overall, continued research into new and effective therapies for BD is crucial for improving the lives of those affected by this condition.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available